Browsing Tag
Neurocrine Biosciences
7 posts
Could Neurocrine’s $2.9bn Soleno deal turn VYKAT XR into its next rare-disease blockbuster?
Neurocrine is buying Soleno for $2.9 billion to add VYKAT XR. Read what the deal means for NBIX growth, rare-disease strategy, and investor sentiment.
Can CRENESSITY’s weight-loss benefit open doors for off-label interest in broader metabolic disorders?
Neurocrine Biosciences’ CRENESSITY shows weight-loss benefits in CAH—could this rare disease drug spark interest in obesity and insulin resistance care?
Neurocrine Biosciences’ one-year CAHtalyst phase 3 data shows sustained weight and insulin-resistance benefits in CAH patients
Neurocrine Biosciences’ CRENESSITY Phase 3 data shows strong weight and metabolic benefits in CAH—see what this means for NBIX stock and future sales.
Gold, energy, and rare earth stocks dominate U.S. market gains amid trade pressures and fed uncertainty
Explore why gold, energy, and rare earth companies led U.S. stock market gains on April 16, 2025, as investors reacted to trade tensions and rate policy fears.
FDA approves CRENESSITY: A breakthrough treatment from Neurocrine Biosciences for classic congenital adrenal hyperplasia
Neurocrine Biosciences has announced US Food and Drug Administration (FDA) approval of CRENESSITY, marking a significant milestone in…
Zydus Lifesciences gets FDA tentative approval for Valbenazine Capsules
Zydus Lifesciences (previously called Cadila Healthcare) said that its subsidiary Zydus Worldwide DMCC has been given tentative approval…
FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia
Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication,…